Drug
Daridorexant clinical trials
Also written ACT-541468.
- studies test it
- 46
- open now
- 12
- in phase 3
- 6
- first study started
- 2015
Keep track of what changes. Save the daridorexant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
45 studies that test it; most in 2018 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 2 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 24
- Phase 2
- 8
- Phase 3
- 6
- Phase 4
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 12
Idorsia Pharmaceuticals Ltd. (31) · University of Rochester (2) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · Nxera Pharma Korea Co., Ltd. (1) · Wang Fengmei (1) · Xuanwu Hospital, Beijing (1) · Sterling McPherson (1) · Institut d'Investigació Biomèdica de Bellvitge (1)
Often tested with
Tested in the same studies.
Midazolam (2) · Rosuvastatin (1) · Warfarin (1) · Famotidine (1) · Efavirenz (1) · Zopiclone (1) · Citalopram (1) · Diltiazem (1)
Studies
Open first, then newest update. How each study uses daridorexant is read from its arms, and is right about nine times in ten.
Testing it · 46
- Daridorexant for Sleep Disturbance in Adults With Liver CirrhosisNot yet recruitingPhase 4Wang FengmeiNCT07830303Written as Daridorexant
- A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the DayNot yet recruitingPhase 3Idorsia Pharmaceuticals Ltd.NCT07843329Written as Daridorexant
- Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients（EASY-TIP）Not yet recruitingPhase 4Xuanwu Hospital, BeijingNCT07733414Written as Daridorexant
- Daridorexant for People With Insomnia and Alcohol Use Disorder StudyNot yet recruitingPhase 2Sterling McPhersonNCT07701928Written as Daridorexant
- Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer DiseaseRecruitingPhase 4University Hospital, MontpellierNCT05924425Written as Daridorexant 50 mg
- Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia SymptomsRecruitingPhase 4Brigham and Women's HospitalNCT07136415Written as Daridorexant
- Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and InsomniaNot yet recruitingPhase 4Institut d'Investigació Biomèdica de BellvitgeNCT07555743Written as Daridorexant 50 mg
- Daridorexant for Alcohol Use DisorderNot yet recruitingPhase 2Johns Hopkins UniversityNCT07532252Written as Daridorexant 50 mg
- Dual Orexin Antagonism and Emotion and Affective Processing StudyRecruitingPhase 4University of OxfordNCT07267559Written as Daridorexant 50 mg
- Impact of Daridorexant on Sleep, Daytime Alertness, and SmokingNot yet recruitingPhase 4Legacy Health SystemNCT07328594Written as Daridorexant 50 mg
- Daridorexant to Prevent Post-cardiotomy DeliriumRecruitingPhase 2University of RochesterNCT07217912Written as Daridorexant 50 mg
- Daridorexant for Alzheimer Disease PreventionRecruitingPhase 2Douglas Mental Health University InstituteNCT07213349Written as Daridorexant 50 mg
- Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia DisorderCompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT05423717Written as Daridorexant 10 mg
- A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia DisorderCompletedPhase 3Nxera Pharma Korea Co., Ltd.NCT07028697Written as Daridorexant
- Daridorexant to Prevent Delirium After Heart SurgeryCompletedPhase 2University of RochesterNCT06630390Written as Daridorexant 50 mg
- A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid NocturiaCompletedPhase 4Idorsia Pharmaceuticals Ltd.NCT05597020Written as Daridorexant
- A Study of Daridorexant in Chinese Patients With Insomnia DisorderCompletedPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06010693Written as Daridorexant
- Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy SubjectsCompletedPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06326723Written as Daridorexant
- A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese ParticipantsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT05877222Written as Daridorexant 10 mg
- A Study to Measure Daridorexant in Breast Milk of Healthy Lactating WomenCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT05632393Written as Daridorexant
See all 46 studies that test daridorexant →
As the comparator · 1 — what is tested is compared with daridorexant
Codes
What other systems call daridorexant · ClinicalTrials.gg INT001169
- MeSH (NLM) C000634383daridorexantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LMQ24G57E9DARIDOREXANTConfirmed FDA, NLM, Wikidata
- RxNorm 2591497One source FDA
- Wikidata Q55112806daridorexantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174674DaridorexantOne source FDA
- DrugBank DB15031One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634383 | daridorexant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LMQ24G57E9 | DARIDOREXANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2591497 | — | One source FDA |
| Wikidata | Q55112806 | daridorexant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174674 | Daridorexant | One source FDA |
| DrugBank | DB15031 | — | One source Wikidata |
Also registered as daridorexant hydrochloride (UNII 9X9581N56R · RxNorm 2591496).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.